Meeting
2020 ASCO Virtual Scientific Program
The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy: Results of 2 consecutive studies in a single referral institution.
Authors
Jaume Mora
Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain
Jaume Mora , Alicia Castañeda , Miguel Angel Flores , Vicente Santa-María , Moira Garraus , Maite Gorostegui , Margarida Simao , Sara Perez-Jaume , Salvador Mañe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10539)
DOI
10.1200/JCO.2020.38.15_suppl.10539
Abstract #
10539
Poster Bd #
426
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
First Author: Holger N. Lode
Poster
2022 ASCO Annual Meeting
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
First Author: Godfrey Chi-Fung Chan
Poster
2020 ASCO Virtual Scientific Program
Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.
First Author: Ami Vijay Desai
Poster
2018 ASCO Annual Meeting
A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).
First Author: Araz Marachelian